Clinical Trial Update: A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 randomized trial comparing the novel agent T1695 with ciclosporin for moderate to severe vernal keratoconjunctivitis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vernal Keratoconjunctivitis

Drugs mentioned

• Ciclosporin (cyclosporine)
• T1695

Snippet

Sponsor: Laboratoires Thea | Conditions: Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | Status: RECRUITING